Electroencephalogram Based Biomarkers for Detection of Alzheimer’s Disease
share
Alzheimer’s disease (AD) is an age-related progressive and neurodegenerative disorder, which is characterized by loss of memory and cognitive decline. It is the main cause of disability among older people. The rapid increase in the number of people living with AD and other forms of dementia due to the aging population represents a major challenge to health and social care systems worldwide. Degeneration of brain cells due to AD starts many years before the clinical manifestations become clear. Early diagnosis of AD will contribute to the development of effective treatments that could slow, stop, or prevent significant cognitive decline. Consequently, early diagnosis of AD may also be valuable in detecting patients with dementia who have not obtained a formal early diagnosis, and this may provide them with a chance to access suitable healthcare facilities. An early diagnosis biomarker capable of measuring brain cell degeneration due to AD would be valuable. Potentially, electroencephalogram (EEG) can play a valuable role in the early diagnosis of AD. EEG is noninvasive and low cost, and provides valuable information about brain dynamics in AD. Thus, EEG-based biomarkers may be used as a first-line decision-support tool in AD diagnosis and could complement other AD biomarkers.
READ FULL TEXT
